On November 6, at the 8th China International Import Expo,AliHealth and Eli Lilly China Reach Strategic Cooperation,Both parties will focus on the management of chronic diseases such as diabetes, and work together in three major areas: digital patient support, doctor-patient education, and collaborative innovation, to jointly create a full-chain digital experience from patient education to diagnosis and treatment services.AliHealth Executive Director and CEO Diefan Shen (right) and Eli Lilly and Company Vice President and China General Manager Dehlan (left) represent the signing.Currently, the burden of chronic diseases in China continues to increase. According to a research report published in The Lancet in 2024, the number of adult diabetes patients in China reached approximately 148 million in 2022, accounting for 18% of the global total of adult diabetes cases. Among diabetes patients aged 30 and above, 78 million have not yet received treatment. However, the "Medium- and Long-Term Plan for the Prevention and Treatment of Chronic Diseases in China (2023-2030)" points out that the standardized management rate for key chronic diseases in China remains below 60%. Patients generally face practical challenges such as gaps in post-hospital management, unstable drug supply, and lack of professional guidance.Against this backdrop, digital means have become a key pathway to solving the challenges of chronic disease management. AliHealth, as a leading online healthcare platform in China, boasts the ability to reach over 300 million users across the country and an efficient pharmaceutical supply chain network that covers hundreds of cities in China. Meanwhile, through AI empowerment, the platform continuously enhances operational efficiency and service quality.In terms of post-diagnosis disease management, AliHealth can provide services covering medication guidance, lifestyle intervention, and companion-style follow-up visits, creating a full-cycle health management solution encompassing "prevention—diagnosis and treatment—management."For innovative drugs like GLP-1 that require cold chain transportation at 2°C to 8°C, the platform also offers customized temperature-controlled logistics solutions to ensure compliance, safety, and efficiency throughout the storage and distribution process, effectively safeguarding patients' medication experience and treatment outcomes.Eli Lilly and Company, with nearly 150 years of history, has deep scientific research accumulation and an innovative drug pipeline in fields such as endocrinology and metabolism. As one of the earliest multinational pharmaceutical companies to enter the Chinese market, Eli Lilly China has consistently promoted the localization of innovative therapies and actively participated in building China's chronic disease prevention and control system, helping to improve the accessibility and management level of major disease diagnosis and treatment.AliHealth CEO and Executive Director Difan Shen said at the signing ceremony: "With medical advancements and increased social awareness, chronic disease management is increasingly showing规模化 (规模化 - scalable) and 标准化 (标准化 - standardized) trends. AliHealth will continue to help pharmaceutical companies improve the accessibility of innovative drugs, collaborate with pharmaceutical companies to efficiently meet market demands, and provide users with full-cycle, more inclusive health solutions, enabling patients to access scientific, continuous, and personalized health guidance anytime, anywhere."First Trial | Huang Jia
Second Review | Li Fangchen
Third Review | Li Jingzhi
